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Protein–proteinHuman papillomavirus 16 E1 and E2 interact with cellular factors to replicate the viral genome. E2 forms
homodimers and binds to 12 bp palindromic sequences adjacent to the viral origin and recruits E1 to the
origin. E1 forms a di-hexameric helicase complex that replicates the viral genome. This manuscript
demonstrates that E1 stabilises the E2 protein, increasing the half life in both C33a and 293 T cells
respectively. This stabilisation requires a direct protein–-protein interaction. In addition, the E1 protein
enhances E2 transcription function in a manner that suggests the E1 protein itself can contribute to
transcriptional regulation not simply by E2 stabilisation but by direct stimulation of transcription. This
activation of E2 transcription is again dependent upon an interaction with E1. Overall the results suggest that
in the viral life cycle, co-expression of E1 with E2 can increase E2 stability and enhance E2 function.).
l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
Human papillomaviruses (HPVs) are episomal double stranded DNA
viruses that infect thedifferentiating epitheliumand cause awide rangeof
lesions. Many HPV types infect the genital tract and they can be
characterised into two groups; low-risk HPVs (−6 and−11) that cause
benign tumours and high-risk HPVs (−16, −18, −31, −33) that are
carcinogenic.
HR-HPV DNA can be detected in more than 99% of cervical
squamous cell carcinomas (Walboomers et al., 1999). Most docu-
mented is HPV16 and this type has a well deﬁned aetiological role in
cervical cancer (Clifford et al., 2003). The life cycle of all HPV is linked
to the differentiation of epithelial cells and viral replication occurs in
three stages. The ﬁrst is the establishment phase of viral replication
where the virus infects epithelial cells and increases copy number to
around 50 per cell. The second is the maintenance phase where viral
episomes are maintained at a constant copy number in dividing cells
of the basal epithelium acting as a reservoir for virus entering
differentiation. The third phase is ampliﬁcation that takes place in the
upper layers of the differentiating epithelium resulting in an increase
of genome copy number to around 1000 per cell, precedingencapsidation and viral egress (McBride, 2008). The two viral proteins
that are absolutely essential for replication are E1 and E2.
E2 consists of two conserved domains separated by a middle hinge
region (Giri and Yaniv, 1998). The N-terminal domain is important for
regulating viral transcription, interaction with E1 and other cellular
factors (Mohr et al., 1990; Storey et al., 1995; Sakai et al., 1996). The C-
terminal domain mediates homodimerisation and DNA binding to
12 bp palindromic target sequences (McBride et al., 1989).
The viral origin of replication is located within the LCR of the HPV
episome. E2 initiates replication by binding to target sites within the
origin. The amino terminal domain of E2 then recruits the ATP
dependent viral helicase E1 to the viral origin (Mohr et al., 1990). E1
and E2 are the only viral proteins required for replication however E1
recruits cellular replication factors to the viral origin in order to
successfully copy the viral genome (Clower et al., 2006; Conger et al.,
1999; Loo and Melendy, 2004; Masterson et al., 1998; Melendy et al.,
1995; Park et al., 1994; Podust et al., 1995).
During the viral life cycle, E2 is also involved in viral genome
partitioning duringmitosis. To do this, E2 interactswith the chromatin via
its amino terminus and the viral genome with its carboxyl terminus.
Different types of viruses appear to use different strategies. For example
HPV-11 E2 binds directly to themitotic spindle (Dao et al., 2006; Van Tine
et al., 2004), HPV-8 E2 uses ribosomal DNA loci (Poddar et al., 2009), BPV-
1 E2 uses Brd4 (Baxter et al., 2005; You et al., 2004) and ChLR1 (Parish
et al., 2006). The receptor for HPV16 E2 remains to be fully determined
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(Donaldson et al., 2007).
In addition to binding to the origin and recruiting E1 for replication
initiation, E2 also regulates transcription from the adjacent E6
promoter. Changes in E2 levels repress or activate the expression on
the oncogenes E6 and E7 (Bouvard et al., 1994; Steger and Corbach,
1997). Previous studies with HPV16 and 18 have demonstrated that
E1 can increase E2 transcriptional activity (Demeret et al., 1998;
Piccini et al., 1995) while BPV-1 E1 has been shown to both repress
(Ferran andMcBride, 1998; Sandler et al., 1993) and activate (Le Moal
et al., 1994; Parker et al., 2000) E2 transcription.
Recent studies have demonstrated cellular factors Brd4 and Tax1BP1
can regulate E2 protein stability (Gagnon et al., 2009; Lee and Chiang,
2009; Wang et al., 2009; Zheng et al., 2009) while the E4 protein
(E1^E4) of HPV-16 binds to E2 directly to increase stability (Davy et al.,Fig. 1. E1 increases E2 protein levels: (a) 293 T cells were co-transfected with 2 μg of E2 and
harvested and prepared for western blot analysis. Antibodies against E2 (TVG261), HA-E1 (
there is more E2 compared with lane 2 demonstrating that HA-E1 increases E2 protein levels
a similar experiment was repeated using an E1 plasmid known to have replicative functions
Rep plasmid. Western blot analysis was carried out as described in (a). Again, in lane 3 the
There is no antibody for E1 that can be used to conﬁrm E1 expression, but this is a functional
chromatin. 2 μg of E2 and/or 1 μg of HA-E1 were transfected into 293 T cells. Proteins were se
1 M. The E2 and HA-E1 proteins were detected using western blot analysis. (d) The chrom
carried out. The results were then graphed as shown with standard error bars represented.
NaCl indicating an increased afﬁnity for chromatin.2009). Here we report that E1 also stabilises E2 via a direct protein–
protein interaction. E1 also enhances E2 transcriptional activity to a
greater degree than the stabilisation would indicate suggesting E1
potentially contributes directly towards transcriptional activation
following interaction with E2. Results demonstrate that understanding
E2 protein turnover should be done in association with E1.
Results
HPV16 E1 increases E2 protein levels
Throughout this manuscript E1 and E2will refer to those of HPV16.
When investigating the interaction between E1 and E2 we noticed
that E2 expression on western blots was always greater in the
presence of E1 (Fig. 1a). As these observations were made with an HA100 ng HA-E1 or 100 ng of carrier plasmid pcDNA 3.1. Forty-eight hours later cells were
HA) and gamma tubulin were used for immunoblotting for protein detection. In lane 3
. (b) To conﬁrm the E2 protein level increase was due to E1 independently of the HA tag,
(HPV-16 E1 Rep). 293 T cells were transfected with 2 μg of E2 and either 0/5/10 μg of E1
re is more E2 compared with lane 2 demonstrating that E1 increases E2 protein levels.
plasmid in DNA replication assays (Sakai et al., 1996). (c) E1 regulation of E2 afﬁnity for
rially extracted using Triton-X lysis buffer with NaCl concentration ranging from 0.15 to
atin afﬁnity assay described in (c) was repeated another two times and densitometry
In the presence of E1 there is a higher percentage of E2 in the higher concentrations of
Fig. 2. E1 stabilises E2. (a) 293 T cells were transfected with 50 ng of HA-E1 and 1 μg of
E2. 48 hours post transfection the cells were treated with CHX for the time points
indicated and cells were then harvested for western blot analysis. When comparing
panel 1 with 3 (without and with HA-E1 respectively) it is clear that the E2 protein
levels are increased at later time points following cycloheximide treatment demon-
strating increased protein half life. (b) The density of the E2 bands were determined
and normalised to gamma tubulin and the results plotted. The graph represents the
standard error of 3 independent experiments. Image J software was used for
quantiﬁcation of the protein bands and therefore made it possible to estimate the
half life of E2; this was increased from 2.6 h to 3.5 h in the presence of HA-E1. (c) 2 μg of
E2 and 1 μg of E1HAwas transfected into 293 T cells. Cells were harvested 48 h later and
E2 RNA levels were detected using real-time PCR. The graph represents 3 experiments
with results normalised to β-actin and standard error bars are shown.
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alternative E1 expression vector lacking this tag with essentially the
same results (Fig. 1b). Although we cannot detect E1 expression from
this plasmid due to lack of appropriate antibodies, it is expressed as it
induces DNA replication (Sakai et al., 1996; King et al., 2010). A
previous study in our laboratory demonstrated that when E2 has
higher afﬁnity for chromatin, the protein becomes more stabilised
(Donaldson et al., 2007). This manifested itself by more E2 protein
being detected in soluble extracts suggesting that E1 may act to shift
E2 onto chromatin and this would explain the increase in E2 protein
levels. To investigate, E2 and E1 were transfected individually or
together into 293 T cells and proteins serially extracted with a range
of salt concentrations, from 0.15 to 1 MNaCl (Fig. 1c). This experiment
was carried out three times and quantitated and the results are
graphed and represented (Fig. 1d). In the presence of E1 there is a
higher percentage of the E2 protein more attached to chromatin. Our
previous studies have demonstrated that E2 protein associated with
chromatin has an increased stability (Donaldson et al., 2007). We
therefore investigated whether the E1 protein was increasing E2
protein stabilisation.
E2 is stabilised by E1
To investigate whether E1 could increase E2 protein stability, E2 half
life experiments were carried out in the absence or presence of E1 in
293 T cells. (Fig. 2a). E2 and E1 transfected cells were treated with the
protein synthesis inhibitor cyclohexamide (CHX) for the indicated time
points. The cellswere then harvested and prepared forwestern blot and
the experiment shown is anexample of three independent experiments.
E2 protein levels decrease after CHX treatment with a half-life of 2.6 h.
However when E2 and E1 are co-transfected together E2 protein
stability is increased and the half-life extended to 3.5 h. E2 levels were
measured from three independent experiments using densitometry and
summarised in Fig. 2b with standard error bars showing, allowing half-
life estimations. Although E1 clearly increases E2 protein half life, we
wanted to also investigate E2 RNA levels in the presence of E1. Fig. 2c
summarises three independent experiments and a small increase in E2
signal is detected in the presence of E1. It should be stressed that the
cycloheximide experiments remove this RNA difference from consid-
eration as it measures protein half life directly.
E2 stabilisation by E1 is a result of a direct interaction between both
proteins
To determine whether E2 stabilisation was a result of a direct
protein interaction with E1, a mutant E2 (E39A) was used. The E39A
mutant has previously been shown to not interact with E1 in vitro
resulting in minimal replication function although it retains normal
transactivation function (Sakai et al., 1996). In order to use the E39A
mutant in this study it was necessary to conﬁrm that E39A did not
directly interact with the E1-HA plasmid in vivo. 293 T cells were co
transfected with a range of concentrations of the E1-HA expression
plasmid and either E2 or the E39A E2 mutant. E1–E2 interaction was
conﬁrmed by coimmunoprecipitation using an antibody against HA
(Fig. 3a). The results demonstrate that within the range of 1 to 100 ng
of E1-HA, co-immunoprecipitation can be detected with E2 wild type
but not with the E39A mutant.
Having established that E39A has a weak interaction with the E1-
HA plasmid, the ability of the mutant E2 to be stabilised by E1 was
assessed (Fig. 3b). In the presence of E1, E39A protein levels are not
stabilised when compared to the E2 wild type (Fig. 2b). E39A protein
half life was calculated as for wild type E2. The quantitated results,
with associated standard errors, are shown in Fig. 3c. The half life of
E39A was calculated to be 2.8 h. The half life was 2.9 h in the presence
of E1. This demonstrates that E1 stabilisation of E2 is a result of the
two viral proteins directly interacting.E1 increases E2 functional activity as a result of a direct interaction
Having established that E1 increases E2 stability, the ability of E1
to alter E2 function was investigated. The ability of E2 to activate
transcription was assessed in the absence and presence of E1 using a
thymidine kinase promoter with six upstream E2 binding sites (Vance
et al., 1999). Titrated E2 was transfected along with the tk6E2
Fig. 3. E2 stabilisation by E1 is a result of a direct interaction between E2 and E1.
(a) 293 T cells were transfected with a range of E1-HA plasmid (0.1/1/10/100 ng) and
either 2 μg of E2 wild type or 2 μg of E39A E2 mutant, a known non-E1 interactor (Sakai
et al., 1996). Cell lysates were harvested 48 h later. To detect E2/E39A interaction with
E1, lysates were immunoprecipitated with the anti-HA antibody. Samples were then
prepared for western blot analysis and immunoblotted with antibodies against E2, HA-
E1 (HA) and gamma tubulin. In lanes 3, 5 and 7 wild type E2 is co-immunoprecipitated
with the HA antibody, while in lanes 4, 6 and 8 it is clear that the E39A mutant is not.
(b) 293 T cells were transfected with 50 ng of HA-E1 and 2 μg of E2 E39A. 48 hours post
transfection the cells were treated with CHX for the time points indicated and cells
were then harvested for western blot analysis. When comparing panel 1 with 3
(without and with HA-E1 respectively) it is clear that the E2 E39A protein levels are not
increased at later time points following cycloheximide treatment demonstrating that
E1 does not increase the half life of this protein. (c) The density of the E2 bands were
determined and normalised to gamma tubulin and the results plotted. The graph
represents the standard error of 3 independent experiments. Image J software was used
for quantiﬁcation of the protein bands and therefore made it possible to estimate the
half life of E2 E39A; there was no signiﬁcant difference in E2 E39A half life in the
absence (2.8 h) or presence (2.9 h) of E1.
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Luciferase activity for the tk6E2 plasmid was normalised to 1 and
other activities were calculated as fold increases over this. The values
shown are an average of three independent experiments carried out
in duplicate. At 1 ng of E2, there is an approximately 9 fold increase in
transcriptional activation in the presence of E1 compared to E2 alone.
At 10 ng of E2, again there is an approximate 9 fold increase and at
100 ng of E2, there is an approximate 4 fold increase in the presence of
E1. Therefore we conclude that E1 greatly increases the amount of E2
transcriptional activation.
The E39A mutant was used in place of E2 wild type and the
experiment was repeated to determine whether this elevation in E2
transcription levels was a consequence of the E1 and E2 proteins
directly interacting (Fig. 4b). The values shown are an average of three
independent experiments. For all concentrations of E39A (1/10/
100 ng) there is a rise in E2 transcriptional activation by approxi-
mately 2 fold when E1 is present. This result perhaps reﬂects an
undetectable residual binding between E1 and E39A, or a slight
increase in E39A RNA levels (Fig. 2c). This result conﬁrms that E1must
directly interact with E2 in order to substantially increase E2
functional activity. It should be noted that the transcriptional
properties of wild type E2 and E2 E39A in the absence of E1 are
very similar, supporting previous observations that this mutation
does not interfere with E2 transcriptional activation properties.Fig. 4. E1 increases E2 transcriptional activity. 1 μg of the tk6E2-luc reporter plasmid
was co-transfected with increasing amounts of (a) E2 or (b) E2 E39A in the absence or
presence of 50 ng of E1HA. Cells were harvested 48 h post transfection and assayed for
luciferase activity. Luciferase activity for lysates containing tk6E2 only was normalised
to 1 and other activities were calculated as fold increases. HA-E1 by itself has no effect
on the tk6E2-luc activity.
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All the data shown in Figs. 1–4 were carried out in 293 T cells. The
ability of E1 tomodulate E2 function in the cervical carcinoma cell line
C33a was also determined. This cell line offers the opportunity to
study HPV function in a cervical cell line without the presence of other
HPV proteins as it is HPV negative. Cycloheximide experiments clearly
demonstrate that, as in 293 T cells, the half life of the E2 protein is
extended in the presence of E1 (Fig. 5a, an example of three
independent experiments). The quantitated results, with associated
standard errors, are shown (Fig. 5b). The half life of E2 in C33A cells
was calculated to be 3.6 h. In the presence of E1 the half life was
increased to 5.7 h. Therefore E1 stabilises E2 in cervical cancer cells.
The effect that E1 has on E2 transcriptional activity was also
investigated (Fig. 5c). At 1 ng of E2, there is an approximate 12 fold
increase in transcriptional activation due to the presence of E1 in
comparison to E2 alone. At 10 ng of E2 there is an approximate 6 fold
increase and at 100 ng of E2, there is an approximate 3.5 fold increase.
The E39A was used in place of E2 wild type in this assay to validate
whether the increase in E2 transcription activation was due to a direct
interaction between E1 and E2. The values shown are an average of
three independent experiments (Fig. 5d). At 1 ng of E39A, there is an
approximate 3 fold increase in transcriptional activation in the
presence of E1 compared to E39A alone. At 10 ng of E39A there is
an approximate 2 fold increase and at 100 ng of E39A, there is anFig. 5. E1 stabilises E2 and increases its functional activity in a cervical cancer cell line. (a) C3
48 hours post transfection, cells were treated with CHX for the time points indicated and harv
E1 respectively) it is clear that the E2 protein levels are increased at later time points followin
the E2 bands were determined and normalised to gamma tubulin and the results plotted. Th
was used for quantiﬁcation of the protein bands and therefore made it possible to estimate th
1 μg of the tk6E2-luc reporter plasmid was co-transfected with increasing amounts of (c) E2
post transfection and assayed for luciferase activity. Luciferase activity for lysates containing
HA-E1 by itself has no effect on the tk6E2-luc activity.approximate 1.2 fold increase in the presence of E1. There is again a
reduction of E1 ampliﬁed E2 transcriptional activation when E1 has
compromised interaction with the E2 protein.
Discussion
E2 is a multifunctional protein which has many roles in the
papillomavirus lifecycle. It is involved in the regulation of viral
transcription, viral genome segregation during mitosis and it anchors E1
to the viral origin of replication to initiate viral replication (McBride,
2008). Disruption of E2 function would therefore potentially disrupt the
viral life cycle at several steps and many studies have focused on
understanding the protein turnover of E2 and the cellular proteins with
which it interacts to execute function. HPV16, 18 and BPV1 E2 are all
targeted by the proteosome for turnover and E2 is ubiquitinated during
this process (Bellanger et al., 2001; Penrose and McBride, 2000; Taylor
et al., 2003) with the half-life measurements ranging from 45min to 3 h.
However, E2 does not exist in isolation as a viral protein in infected cells
and studies have demonstrated that E4 can inﬂuence the stability and
function of the E2 protein (Davy et al., 2009), while E6 can inﬂuence the
function and solubility of E2 (Grm et al., 1995) and L2 regulate the
transcription but not the replication properties of E2 (Okoye et al., 2005).
This report demonstrates that E1 can regulate the stability of the E2
protein via a direct protein–protein interaction and that this stabilisation
enhances E2 transcription function.3A cells were co-transfected with 2 μg of E2 and 2 μg of E1-HA or pcDNA carrier plasmid.
ested for western blot analysis. When comparing panel 1 with 3 (without and with HA-
g cycloheximide treatment demonstrating increased protein half life. (b) The density of
e graph represents the standard error of 3 independent experiments. Image J software
e half life of E2; this was increased from 3.6 h to 5.7 h in the presence of HA-E1. (c and d)
or (d) E2 E39A in the absence or presence of 50 ng of E1HA. Cells were harvested 48 h
tk6E2 only were normalised to 1 and other activities were calculated as fold increase.
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repress E2 transcription function (Ferran and McBride, 1998; Le Moal
et al., 1994; Parker et al., 2000; Sandler et al., 1993) with discrepancies
perhaps originating in different reporter and cell systems. However, for
HPV the picture is clearer. A previous study on regulation of HPV16 E2 by
E1 also demonstrated an activation of E2 transcription function (Piccini et
al., 1995) andhigh riskHPV18E1andE2havea similar interactionwithE1
stimulating E2 transcription (Demeret et al., 1998). In both of these
studies the tk promoter was used to drive transcription, similarly to the
results presented here. However in neither of these studies was the
inﬂuence of E1 on E2 protein levels and stability investigated and our
results presented here suggest that the increase of E2 transcription by E1
may, at least in part, be due to a stabilisation of the E2 protein. Demeret et
al. showed that E1 is a transcriptional activator when fused to the DNA
binding domain of BPV1 E2 demonstrating that it can recruit chromatin
modiﬁcation complexes to promoters. Therefore the stimulation of E2
transcription activity by E1 could be due to a combination of E2 protein
stabilisation and E1 associated proteins contributing to transcriptional
activation. Another possible contributing factor for the stimulation of E2
transcription by E1 could be related to an alteration of E2 interactionwith
transcriptional co-factors when complexed with E1, as was suggested by
Parker et al. to explain stimulation of BPV1 E2 transcription by E1. The
conformation of E2 could be altered such that it has an enhanced
interaction with transcriptional co-factors, of which several have been
identiﬁed includingBrd4 (Boner et al., 2002; Lee andChiang, 2009;Kumar
et al., 2007;Penget al., 2000;Wanget al., 2009;Youet al., 2004). Therefore
the reason for the stimulation of E2 transcription functionbyE1 couldbe a
combination of several factors with stabilisation of E2 being one
contributing factor. What is clear from the data in this report is that E1
must either alter E2 function over and above stabilisation or bring in
transcription factors itself. This can be concluded because at the lowest
level of E2, the E1 protein stimulates muchmore than a 100 fold increase
in the E2plasmid input levelswithout E1 (Figs. 4a and5c). So, althoughE1
does increase E2 protein half life, it does not do it by somuch as to explain
this observation.
HPV16E2 is turnedovervia theproteasome followingubiquitinylation
(Taylor et al., 2003) and therefore E1 presumably stabilises E2 by
preventing this turnover. Recent studies have demonstrated that
expression of the Brd4 C-terminal domain blocks the interaction between
E2 and the cullin-3 complex of the proteosome and therefore increases E2
stability (Zheng et al., 2009), while TaxBP1, an essential component of the
A20 ubiquitin editing complex, also inhibits the proteasomal degradation
of E2 (Wang et al., 2009). It is therefore possible that E1 acts in a similar
manner to block E2 degradation and this would play an important role in
the viral life cycle via increasing E2 protein levels and function.
Alternatively, additional modiﬁcations of E2 may occur following
interaction with E1 that contribute to protein stabilisation and function.
E2 interacts with components of the SUMO family of proteins (Wu et al.,
2008;Wu et al., 2009) while Ubc9 and SUMO1 directly interact with BPV
E1 and HPV11 to regulate DNA replication function (Rangasamy and
Wilson, 2000; Fradet-Turcotte et al., 2009). The interaction betweenUbc9
and E1 was shown to be essential for HPV16 replication (Yasugi et al.,
1997). It is therefore possible that the Sumoylation of the E1 and E2
proteins is involved in the regulation of E2 protein turnover and that the
interaction between the two proteins contributes to altered E2 modiﬁca-
tions regulating stability.
This report demonstrates that the regulation of E2 protein turnover
should be analysed in the presence of E1; E1 is always expressed in an
infected cell at the same time as E2. A full understanding of how this
replication complex is regulated will provide therapeutic targets and
strategies for viral life cycle intervention.
Materials and methods
Cell culture and plasmids. HEK-293 T cells and the human cervical
cancer cell line C33A were cultured in DMEM supplemented with 10%(v/v) foetal calf serum and 1% (v/v) penicillin/streptomycin mixture
(Invitrogen) at 37 °C in a 5% CO2/95% air atmosphere. The E2 plasmid
used was pCMV-16E2 (Bouvard et al., 1994). The HPV16 E1 plasmids
included pCMV-16E1 (Sakai et al., 1996, a kind gift from Peter
Howley) and HPV16-E1 HA tagged. The E1-HA tagged plasmid was a
kind gift from Mart Ustav's laboratory and has been described
previously (Kadaja et al., 2007). The E39A mutation was introduced
into pCMV-16E2 using the Stratagene Quickchange protocol using the
following primers; 5′TATTGGAAACACATGCGCCTAGCATGTGCTATT-
TATTACAAGGCC3′ and 5′GGCCTTGTAATAAATAGCACATGCTAGGCG-
CATGTGTTTCCAATA 3′. pcDNA3.1 (Invitrogen) was used as a carrier
plasmid in all experiments.
Transfection
Cells were plated onto 100 mm plates (60 mm plates for
transcription assay) so as to achieve 80% conﬂuence at harvest. The
following day the plasmids were transfected using the Calcium
Phosphate method of transfection (see King et al., 2010 for more
details).
Western blot
Cells were lysed in NP40 lysis buffer (0.5% NP40, 150 mM NaCl,
50 mM Tris pH 8.0). For Salt Extraction experiments, cell pellets were
serially extracted in CSK buffer with 0.5% Triton X-100 at salt
concentrations ranging from 0–1.0 M NaCl. A detailed protocol has
been described previously (Donaldson et al., 2007). Protein concen-
trationwas determined using a Bradford protein assay. Equal amounts
(20–50 g) of total protein were loaded on a 4–12% gradient gel
(Invitrogen) and run for 1 h at 200 V. Proteins were transferred to a
nitrocellulose membrane using the iBlot system (Invitrogen). The
membranes were blocked in 5% milk in PBS+0.05% Tween. E2 was
detected using TVG261 mouse monoclonal Ab, E1 was detected with
HA.11 clone 16B12 monoclonal antibody (Covance) and gamma
tubulin was detected using the GTU88 mouse monoclonal antibody.
Western Blots were scanned and quantiﬁed using the ImageJ
software. Each quantiﬁcation is an average of three experimental
repeats. In the protein half life experiment blots were quantiﬁed and
E2 levels relative to pre-cycloheximide treatment were plotted. E2
was normalised to γ tubulin. In the salt extraction experiment blots
were quantiﬁed and E2 levels in each salt fraction were plotted as a
percentage of the E2 total for each nuclear extract.
Immunoprecipitation
300 μg of protein lysates was incubated with HA antibody
overnight at 4 °C on a rotor. The following day protein A sepharose
beads (Sigma) were added to the lysates to post clear for 1–2 h. The
lysate/bead mix was centrifuged brieﬂy and the lysate was removed.
Protein G sepharose beads (Sigma) were added to the lysates for
another overnight incubation. After 5 washes, the beads were boiled
in 15 μl of LDS buffer (Invitrogen) and 5 μl of sample reducing agent
(Invitrogen). The beads and buffer were treated by electrophoreses
using the western blot method described previously.
Protein half-life assay
At 48 hour post transfection, cells were treated with 100 μg/ml of
cyclohexamide (Sigma) for time points indicated in the legend
ﬁgures. Cells were harvested and prepared for western blot. Protein
half-life was determined using ImageJ and Microsoft Excel software.
See (Johansson et al., 2009) for more details. To estimate the half-life
from the presented graphs, best ﬁt lines were taken and the equation
of this line used to determine the half life.
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Cellswere transfectedwith theE2-responsive reporter plasmidpGL3-
tk6E2 (Vance et al., 1999). 1 μg of reporter plasmid was transfected in
each assay and the results shown are of three independent experiments
carried out in duplicate using the protocol described previously (Taylor
et al., 2003). Brieﬂy the HPV replication plasmids and pGL3-tk6E2 were
co transfected into 293 T/C33A cells. Forty eight hours post transfection
the cells were harvested and assayed for luciferase activity (Promega).
RNA extraction
Cells were harvested and RNA extracted using RNeasy Mini Kit
(Qiagen). The DNA was removed from the samples using DNA-free
(Ambion) and then cDNA was synthesised using Afﬁnity Script
(Stratagene). Real-time qPCR was used to quantify HPV 16 E2 RNA
levels using beta actin as an endogenous control. Probe and primers
for E2 were as follows; Fwd Primer 5′CCTGAAATTATTAGGCAG-
CACTTG3′, Rev Primer 5′GCGACGGCTTTGGTATGG3′, Probe 5′FAM-
CAACCACCCCGCCGCGA-TAMRA3′.
Site directed mutagenesis
The E39A point mutation was introduced into the pHPV16 E2
sequence by a PCR-directed mutagenesis method using KOD Hot Start
Polymerase kit (Merck). The primers were designed to change a
glutamic acid at residue 39 with an alanine (available on request).
Input plasmid DNA was then digested using Dpn1. The newly
synthesised mutated plasmid was cleaned up using phenol-chloro-
form and ethanol precipitation techniques and transformed into
DH5α competent cells (Invitrogen). DNA was extracted from bacteria
culture and sequencing reactions were prepared using ABI Prism®
BigDye®Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems).
Following puriﬁcation the reactions were resuspended in 25 μl Hi-Di
formamide and analysed using an ABI 300 automatic sequencer.
Salt extraction
Cell pellets were lysed in CSK buffer (10nM PIPES pH6.8, 100 mM
NaCl, 300 mM sucrose, 3 mM MgCl2, 1 mM EGTA) containing 0.5%
Triton X-100, and the insoluble material was pelleted. The pellet was
then serially extracted with increasing concentrations of NaCl in CSK
(0.2/0.4/0.6/0.8/1.0M) and the extracted lysates were prepared for
western blot analysis.
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